Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
No Thumbnail Available
Date
2023
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference. © 2023 Future Medicine Ltd.
Description
Keywords
Aminopyridines , Antineoplastic Combined Chemotherapy Protocols , Breast Neoplasms , Female , Humans , Letrozole , Receptor, ErbB-2 , Retrospective Studies , Treatment Outcome , epidermal growth factor receptor 2 , estrogen receptor , letrozole , palbociclib , progesterone receptor , ribociclib , aminopyridine derivative , antineoplastic agent , epidermal growth factor receptor 2 , letrozole , palbociclib , ribociclib , adult , aged , anemia , Article , clinical feature , cohort analysis , controlled study , drug dose reduction , drug efficacy , drug preference , drug withdrawal , estrogen receptor-positive, HER2-negative breast cancer , febrile neutropenia , female , hormone receptor-positive, HER2-negative breast cancer , hormone sensitivity , human , hypertransaminasemia , liver toxicity , major clinical study , male , neutropenia , overall survival , progesterone receptor positive breast cancer , progression free survival , retrospective study , thrombocytopenia , breast tumor , pathology , treatment outcome